II Therapy of chronic hepatitis C

Biomedical Research Reports

Volumn 2, Issue C, 2000, Pages 203-239

  McHutchison, John G ^a   Hoofnagle, Jay H ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957125323     PISSN: 18745326     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-5326(00)80015-0     Document Type: Article

References (83)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
2. Detre K.M., Belle S.H., and Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 2 (1996) 219-228
3. Hoofnagle J.H., Mullen K.D., Jones D.B., et al. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315 (1986) 1575-1578
4. Carithers R.L., and Emerson S.S. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 25 Suppl 1 (1997) 83S-88S
5. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339 (1998) 1485-1492
6. Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 (1998) 1426-1432
7. National Institutes of Health Consensus Development Conference Panel. Statement: management of hepatitis C. Hepatology 26 Suppl 1 (1997) 2S-10S
8. EASL International Consensus Conference on Hepatitis C Panel. Consensus Statement. J Hepatol 30 (1999) 956-961
9. Seeff L.B. Natural history of hepatitis C. Hepatology 26 Suppl 1 (1997) 21S-28S
10. Hoofnagle J.H. Hepatitis C: the clinical spectrum of disease. Hepatology 26 Suppl 1 (1997) 15S-20S
11. Fattovich G., Giustina G., Degos F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112 (1997) 463-472
12. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349 (1997) 825-832
13. Mathurin P., Moussalli J., Cadranel J.F., et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 27 (1998) 868-872
14. Lindsay K.L. Therapy of hepatitis C: overview. Hepatology 26 Suppl 1 (1997) 71S-77S
15. Marcellin P., Boyer N., Gervais A., et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127 (1997) 875-881
16. Lau D., Kleiner D.E., Ghany M.G., Park Y., Schmid P., and Hoofnagle J.H. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 28 (1998) 1121-1127
17. Wong J.B., Bennett W.G., Koff R.S., and Pauker S.G. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 280 (1998) 2088-2093
18. Koff R.S. Therapy of hepatitis C: cost-effectiveness analysis. Hepatology 26 Suppl 1 (1997) 152S-155S
19. Bonkovsky H.L., Woolley J.M., and Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 29 (1999) 264-270
20. Koff R.S. Impaired health-related quality of life in chronic hepatitis C: the how, but not the why. Hepatology 29 (1999) 277-279
21. Davis G.L., Balart L.A., Schiff E.R., et al. Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. J Hepatol 11 (1990) S31-S35
22. Farrell G.C., Bacon B.R., and Goldin R.D. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Hepatology 27 (1998) 1121-1127
23. Tong M.J., Reddy K.R., Lee W.M., et al. Treatment or chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology 26 (1997) 747-754
24. Lee W.M. Therapy of hepatitis C: interferon alfa-2a trials. Hepatology 26 Suppl 1 (1997) 89S-95S
25. Tine F., Magrin S., Craxi A., and Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 13 (1991) 192-199
26. Poynard T., Leroy V., Cohard M., et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24 (1996) 778-789
27. Poynard T., Bedossa P., Chevallier M., et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 332 (1995) 1457-1462
28. Neumann A.U., Lam N.P., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998) 103-107
29. Lam N.P., Neumann A.U., Gretch D.R., Wiley T.E., Perelson A.S., and Layden T.J. Dose-dependent acute clearnace of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26 (1997) 226-231
30. Bonkovsky H.L. Therapy of hepatitis C: other options. Hepatology 26 Suppl 1 (1997) 152S-155S
31. Patterson J.L., and Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 12 (1990) 1139-1146
32. Hultgren C., Milich D.R., Weiland O., and Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 79 (1998) 2381-2391
33. Bodenheimer H.C., Lindsay K.L., Davis G.L., Lewis J.H., Thung S.N., and Seeff L.B. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: multicenter trial. Hepatology 26 (1997) 473-477
34. Di Bisceglie A.M., Conjeevaram H.S., Fried M.W., et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 897-903
35. Dushieko G.M., Mann J., Thomas H., et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 25 (1996) 591-598
36. Hoofnagle J.H., Lau D., Conjeevaram H., Kleiner D., and Di Bisceglie A.M. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepatitis 3 (1996) 247-252
37. Lai M.Y., Kao J.H., Yang D.M., et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 111 (1996) 1307-1312
38. Chemello L., Cavalletto L., Bernardinello E., Guido M., Pontisso P., and Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 23 (1995) 8-12
39. Reichard O., Norkrans G., Fryden A., Braconier J.H., Sonnerborg A., and Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribaviria for chronic hepatitis C. Lancet 351 (1998) 83-87
40. Gretch D. Diagnostic tests for hepatitis C. Hepatology 26 Suppl 1 (1997) 43S-47S
41. Shiratori Y., Kato N., Yokosuka O., et al. Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon. J Hepatol 27 (1997) 437-444
42. Reddy K.R., Hoofnagle J.H., Tong M.J., et al. Racial differences in response to therapy with interferon in chronic hepatitis C. Hepatology 30 (1999) 787-793
43. [abstract]. McHutchison J.G., Poynard T., Gordon S.C., et al. The impact of race on response to anti-viral therapy in patients with chronic hepatitis C. Hepatology 30 (1999) 302A
44. Alberti A., Chemello L., Noventa F., Cavalletto L., and De Salvo G. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 26 Suppl 1 (1997) 137S-142S
45. Davis G.L., Esteban-Mur R., Rustgi V., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339 (1998) 1493-1499
46. Heathcote E.J., Keefe E.B., Lee S.S., et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 27 (1998) 1136-1143
47. [abstract]. Di Marco V., Almasio P.L., Vaccaro A., et al. Combined treatment of relapse of chronic hepatitis C with high-dose alfa-2b interferon plus ribavirin for 6 or 12 months. Hepatology 30 (1999) 303A
48. Poynard T., Leroy V., Mathurin P., Cohard M., Opolon P., and Zarski J.P. Treatment of chronic hepatitis C by interferon for longer duration than six months. Dig Dis Sci 41 (1996) 99S-102S
49. Sobesky R., Mathurin P., Charlotte F., et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 116 (1999) 378-386
50. Shiffman M.L., Hofmann C.M., Thompson E.B., et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 26 (1997) 780-785
51. [abstract]. Min A.D., Jones J.L., Lebovics E., et al. Interferon alfa-2b and ribavirin in patients with resistant chronic hepatitis C. Hepatology 30 (1999) 192A
52. [abstract]. Frider B., Findor J.A., Perez V., et al. Response to 12-month treatment with interferon alfa-2b plus ribavirin in patients with chronic hepatitis C relapsers or non-reponders to a previous interferon treatment. Hepatology 30 (1999) 196A
53. Alter H.J., Congry-Cautilena C., Melpolder J., et al. Hepatitis C in asymptomatic blood donors. Hepatology 26 Suppl 1 (1997) 29S-33S
54. Shakil O.A., Conry-Cantilena C., Alter H.J., et al. Volunteer blood donors with antibodies to hepatitis C virus: clinical, biochemical, virological and histological features. Ann Intern Med 123 (1995) 330-337
55. [abstract]. Ryder S.D. Progression of liver fibrosis in mild hepatitis C. A prospective paired liver biopsy study. Hepatology 30 (1999) 316A
56. Marcellin P., Levy S., and Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 26 Suppl 1 (1997) 133S-136S
57. Serfaty L., Chazouillieres O., Pawlotsky J.M., Andreani T., Pellet C., and Poupon R. Interferon alpha therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 110 (1996) 291-295
58. Ideo G., Bellobuono A., Tempini S., Bellati G., Romano L., and Zanetti A.R. Interferon treatment of chronic hepatitis C patients with normal or near normal alanine aminotransferase levels: might it be harmful rather than useful?. Int Hepatol Commun 6 (1996) 8-15
59. Areias J., Pedroto I., Freitas T., et al. Hepatitis C virus carriers with normal ALT activity: viremia, genotype and effect of interferon therapy. Gastroenterology 110 (1996) A1144
60. Silverman A.L., Piquette E.L., Filipiak C.L., Neill J.S., Bayati N., and Gordon S.C. Alfa interferon treatment of hepatitis C virus RNA positive patients with normal or near-normal alnine aminotransferase levels. Am J Gastroenterol 92 (1997) 1783-1795
61. Nordoy I., Krarup H.B., Bell H., et al. Interferon-alpha 2b therapy in low-activity hepatitis C: a pilot study. Scand J Gastroenterol 32 (1997) 1256-1260
62. Rossini A., Ravaggi A., Biasi L., et al. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology 26 (1997) 1012-1017
63. Orito E., Mizokami M., Suzuki K., et al. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment. J Gastroenterol Hepatol 12 (1997) 58-61
64. Sangiovanni A., Morales R., Spinzi G., et al. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 27 (1998) 853-856
65. Renault P.F., Hoofnagle J.H., Park Y., et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 147 (1987) 1577-1580
66. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 26 Suppl 1 (1997) 112S-121S
67. Vinayek R., and Shakil A.O. Adverse events associated with interferon alfa therapy in patients with chronic viral hepatitis. Viral Hepatitis Rev 3 (1997) 167-177
68. Lisker-Melman M., Di Bisceglie A.M., Usala S.J., Weintraub B., Murray L.M., and Hoofnagle J.H. Development of thyroid disease during therapy of chronic virall hepatitis with interferon alfa. Gastroenterology 102 (1992) 2155-2160
69. Deutsch M., Dourakis S., Manesis K., et al. Thyroid abnormalities in chronic viral hepatiits and their relationship to interferon alfa therapy. Hepatology 26 (1997) 206-210
70. Petrov S. Measurements and application of health-related quality of life in chronic viral hepatitis. Viral Hepatitis Rev 3 (1997) 253-265
71. Papo T., Marcellin P., Bernuau J., Durand F., Poynard T., and Benhamou J.-P. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 116 (1992) 51-53
72. Shindo M., Di Bisceglie A.M., and Hoofnagle J.H. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 102 (1992) 1406-1408
73. Janssen H., Brouwer J.T., Van der Mast R.C., Schalm S.W., and Suicide a.w.a.-i.t.f.c.v.h. J Hepatol 21 (1994) 241-243
74. DiBisceglie A.M., Bacon B.R., Kleiner D.E., and Hoofnagle J.H. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 21 (1994) 1109-1112
75. Davis G.L. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 20 (1994) 1-3
76. Gavier B., Martinez-Gonzalez M.A., Riezu-Boj J.I., et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 113 (1997) 1647-1653
77. Tong M.J., Blatt L.M., McHutchison J.G., Co R.L., and Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 26 (1997) 1640-1645
78. [abstract]. Shiffman M., Pockros P.J., Reddy R.K., et al. A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alfa-2a vs standard interferon alfa-2a for treatment of chronic hepatitis C. Gastroenterology 116 (1999) A1275
79. [abstract]. Heathcote E.J., Shiffman M.L., Cooksley G., et al. Multinational evaluation of the efficacy and safety of once-weekly peg interferon alfa-2a in patients with chronic hepatitis C with compensated cirrhosis. Hepatology 30 (1999) 316A
80. Kim J.L., Morgenstern K.A., Lin K.A., et al. Crystal structure of the hepatitis C virus NS3 protease doman complexed with a synthetic NS4A cofactor peptide. Cell 87 (1996) 343-355
81. Love R.A., Parge H.E., Wickersham J.A., et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc-binding site. Cell 87 (1996) 331-342
82. Yao N., Hesson T., Cable M., et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 4 (1997) 463-467
83. http://www.niddk.nih.gov/health/digest/pubs/chrnhepc/chrnhepc.htm